Oyster Point Pharma to Present at the 2019 ASCRS•ASOA Annual Meeting and at the Ophthalmology Innovation Summit (OIS) Meeting

PRINCETON, N.J.–(BUSINESS WIRE)–Oyster Point Pharma, Inc., a privately held clinical-stage
pharmaceutical company with an initial focus on developing novel
therapies for the treatment of Dry Eye Disease (DED), today announced
multiple data presentations of the company’s product candidates at the
2019 American Society for Cataract and Refractive Surgery (ASCRS•ASOA)
Annual Meeting and at the Ophthalmology Innovation Summit (OIS) meeting,
taking place May 2-7 in San Diego.


The company’s lead product candidates for DED are delivered via an
ocular surface-sparing nasal spray designed to stimulate the trigeminal
parasympathetic pathway to promote natural tear film production. In
Phase 2b clinical studies, patients administered either OC-01 or OC-02
experienced rapid and significant improvements in both the signs and
symptoms of DED. Both were well-tolerated with no significant ocular
adverse events or drug-related serious adverse events.


“I’m excited by the great progress Oyster Point has made this past year
as we prepare to advance our lead product candidate into Phase 3
clinical development,” said Jeffrey Nau, Ph.D., M.M.S., President and
CEO of Oyster Point. “We look forward to sharing data supporting our
novel approach to treating Dry Eye Disease and other important company
updates with the ophthalmology community at the ASCRS•ASOA and OIS
meetings.”


OIS and ASCRS•ASOA presentations include:


Thursday, May 2 (OIS@ASCRS)


A corporate overview, including data from the Phase 2b ONSET-1 study
of OC-01 for the treatment of DED, will be presented by Jeffrey Nau,
Ph.D., M.M.S., President and CEO of Oyster Point– OIS Innovation
Showcase, Hilton San Diego Bayfront, 11:05 a.m. PT


Monday, May 6 (ASCRS•ASOA)


In a session titled, “Oyster Point Pharma: Leveraging Neuroscience to
Treat Dry Eye Disease with a Nasal Spray,” an overview of
pharmacologic stimulation of the trigeminal parasympathetic pathway
and data from the Phase 2b ONSET-1 study of OC-01 for the treatment of
DED will be presented by Dr. Edward Holland, Director of Cornea
Services at Cincinnati Eye Institute and member of Oyster Point
Pharma’s medical advisory board– Industry Spotlight Theater,
Hall C, Booth #1345, 2:28 p.m. PT


Data from the Phase 2b PEARL study of OC-02 for the treatment of DED
will be presented by Dr. Edward Holland– Paper Session, Upper
Level, Room 1B at 1:17 p.m. PT


About Oyster Point Pharma, Inc.


Oyster Point Pharma is a clinical-stage pharmaceutical company
leveraging neuroscience to discover, develop, and commercialize novel
therapies to treat diseases with high unmet needs. The company’s initial
focus is to develop innovative therapeutics to treat the signs and
symptoms of Dry Eye Disease by stimulating the trigeminal
parasympathetic pathway to activate the glands and cells responsible for
tear film production, known as the Lacrimal Functional Unit. Oyster
Point is leveraging a class of molecules called nicotinic acetylcholine
receptor (nAChR) agonists to bind to receptors on the trigeminal nerve,
accessible within the nose, to stimulate natural tear film production.


For more information visit oysterpointrx.com and follow on Twitter at
@OysterPointRx.


Contacts

Krysta Pellegrino650-255-6142Krysta@healthandcommerce.com